This group experienced statistically significant impacts on taking any courses in general and in taking trade-specific courses, but no effect on longer-term earnings.
Intention to treat analysis revealed that the intervention group experienced statistically significant changes in self-perceived pain frequency (P =.000), pain intensity (P =.001), pain duration (P =.000), functional status (P =.000), medication used (p<0.01) and depression (P =.000); these differences retained their significance at the 6-month follow-up.
Results indicate that patients in the sunitinib group experienced statistically significantly milder symptoms of bone pain, fatigue, and fever symptoms.
The group experienced statistically significant improvements in evidence based practice self-efficacy and self-reported behavior (p < 0.001).
Each group experienced statistically significant (p<.0001) and clinically meaningful improvements in pain and function: Mean pain change scores for the once/week and twice/week groups were -2.1 (SD 2.7) and -2.4 (SD 2.2), respectively.
Based on the mean treatment difference for the FACT-G scores, patients in the sunitinib group experienced statistically better cancer-specific HRQoL compared with patients in the IFN-α group at each time point (Table 6).
Patients in the abatacept group experienced statistically significantly greater improvements from baseline in the PCS (p<0.001) and MCS (p = 0.004) of the SF-36, and in each of the eight individual subscales compared with placebo, following 6 months of treatment (fig 4A).
Results: Results consistently showed that patients in sunitinib group experienced statistically significantly milder kidney-related symptoms, better cancer-specific HRQoL and general health status (in social utility scores) during the study period as measured by these patient-reported outcome end points.
Intention to treat analysis revealed that the intervention group experienced statistically significant changes in self-perceived pain frequency (p<.001), pain intensity (p=.001), pain duration (p<.001), functional status (p<.001), medication used (p<0.01) and depression (p<.001); these differences retained their significance at the 6-month follow-up.
Both groups experienced a statistically significant early (3 months after surgery) improvement of anxiety scores, which persisted until the 24-month evaluation.
